SCHEMBL23144697

SCHEMBL23144697

C#CCN(C(=O)O)c1ccc(S(C)(=O)=O)cc1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ DRD3 P35462 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ STAT6 P42226 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ KEAP1 Q14145 2/20 0.40
▸ NFE2L2 Q16236 2/20 0.40
▸ ACHE P22303 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.36
▸ TOP2B Q02880 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ IRAK4 Q9NWZ3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23144153 0.86 HRH4 (0.40) KCNH2KEAP1NFE2L2PTGDR2
SCHEMBL23144640 0.85 SMN1; SMN2 (0.40) LMNATSHRADRA2ACYP2D6CYP2C9
SCHEMBL29811519 0.85 SMN1; SMN2 (0.40) LMNATSHRADRA2ACYP2D6CYP2C9
SCHEMBL23144699 0.82 LMNA (0.44) LMNAPTGDR2ALDH1A1MAOB
SCHEMBL23144835 0.79 HRH4 (0.43) LMNACYP2C9PTGDR2
SCHEMBL23144127 0.79 APEX1 (0.39) TSHRSMN1; SMN2ALDH1A1POLB
SCHEMBL23144041 0.79 ACHE (0.49) TSHRCYP2C9SMN1; SMN2ACHEMAPK1
SCHEMBL23144634 0.78 PTGDR2 (0.36) LMNATSHRADRA2ACYP2D6CYP2C9
SCHEMBL23144039 0.77 ACHE (0.45) LMNAACHEALDH1A1MAOB
SCHEMBL19252076 0.76 CA12 (0.44) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025031471-A1 NOVEL HETEROCYCLIC COMPOUND FOR REGULATING P53 FUNCTION 德睿智药(苏州)新药研发有限公司 2025-02-13 — — WO disclosed
US-11814373-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-11-14 — — US disclosed
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. 2023-10-05 — — US disclosed
WO-2021061643-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION PMV PHARMACEUTICALS, INC. (US) 2021-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312539-A1 METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION TP53, TP53BP1, KRAS LMNA 2920/4885TSHR 3846/4885ADRA2A 4716/4885
US-11814373-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, KRAS LMNA 2920/4885TSHR 3846/4885ADRA2A 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback